** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23
** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg
** Adds, Eli Lilly's LLY.N orforglipron also in spotlight
** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say
** YTD, NOVOb is down 16.7%
** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch
** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure
** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar
** It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601
(Reporting by Anna Pruchnicka)
((anna.pruchnicka@tr.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.